SIMVASTATIN (MK 733) IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - A 2-YEAR TRIAL

被引：0
|
作者：
LECLERCQ, V
HARVENGT, C
机构：
[1] CATHOLIC UNIV LOUVAIN, PHARMACOTHERAPY LAB, 53 AVE E MOUNIER, B-1200 BRUSSELS, BELGIUM
[2] ST LUC UNIV CLIN, DEPT INTERNAL MED, B-1200 BRUSSELS, BELGIUM
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 1989年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：76 / 81
页数：6
相关论文
共 50 条
  • [41] Effect of different doses of simvastatin on soluble cell adhesion molecule (sCAM) levels in patients with heterozygous familial hypercholesterolemia (hFH)
    Alonso, R
    Badimon, L
    de Andres, R
    Villacastin, B
    Campos, T
    Mata, P
    ATHEROSCLEROSIS, 1999, 144 : 32 - 32
  • [42] HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH PATHOLOGICAL EXERCISE-INDUCED LEAKAGE OF MUSCLE PROTEINS, WHICH IS NOT AGGRAVATED BY SIMVASTATIN THERAPY
    SMIT, JWA
    BAR, PR
    GEERDINK, RA
    ERKELENS, DW
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (02) : 79 - 84
  • [43] Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain
    Real, JT
    Chaves, FJ
    Civera, M
    Garcia-Garcia, AB
    Ascaso, JF
    Armengod, ME
    Carmena, R
    MEDICINA CLINICA, 2001, 116 (03): : 81 - 85
  • [44] EFFECT OF SIMVASTATIN (MK-733) ON THE REGULATION OF CHOLESTEROL-SYNTHESIS IN HEP G2 CELLS
    NAGATA, Y
    HIDAKA, Y
    ISHIDA, F
    KAMEI, T
    BIOCHEMICAL PHARMACOLOGY, 1990, 40 (04) : 843 - 850
  • [45] DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL OF PROBUCOL IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    DURRINGTON, PN
    MILLER, JP
    ATHEROSCLEROSIS, 1985, 55 (02) : 187 - 194
  • [46] Statin therapy and secretory phospholipase A2 in children with heterozygous familial hypercholesterolemia
    Braamskamp, Marjet J. A. M.
    Tsimikas, Sotirios
    Wiegman, Albert
    Kastelein, John J. P.
    Hutten, Barbara A.
    ATHEROSCLEROSIS, 2013, 229 (02) : 404 - 407
  • [47] EFFECTS OF SYNVINOLINE (MK-733) ON SERUM LEVELS OF LIPOPROTEINS AND APOPROTEIN-A1 AND APOPROTEIN-B IN 24 PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    AUBERT, I
    EMMERICH, J
    CHARPAK, Y
    CHANU, B
    DACHET, C
    ERLICH, D
    BESSEAU, M
    ROUFFY, J
    JACOTOT, B
    ANNALES DE MEDECINE INTERNE, 1988, 139 (04): : 296 - 296
  • [48] INFLUENCE OF SPECIFIC MUTATIONS AT THE LDL-RECEPTOR GENE LOCUS ON THE RESPONSE TO SIMVASTATIN THERAPY IN AFRIKANER PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    JEENAH, M
    SEPTEMBER, W
    VANROGGEN, FG
    DEVILLIERS, W
    SEFTEL, H
    MARAIS, D
    ATHEROSCLEROSIS, 1993, 98 (01) : 51 - 58
  • [49] EFFECT OF 5-YEAR ADMINISTRATION OF PROBUCOL ON DEVELOPMENT OF MYOCARDIAL-INFARCTION IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    SHINOMIYA, M
    NISHIDE, T
    TASHIRO, J
    SHIRAI, K
    SAITO, Y
    YOSHIDA, S
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (02): : 142 - 151
  • [50] A 3-YEAR OPEN-LABEL STUDY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Langslet, Gisle
    Breazna, Andrei
    Drogari, Euridiki
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1978 - 1978
12345